<DOC>
	<DOC>NCT00642902</DOC>
	<brief_summary>To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.</brief_summary>
	<brief_title>A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis of RMS (as per McDonald criteria, 2005) Other protocoldefined inclusion criteria could apply. Have primary progressive multiple sclerosis (MS) Have secondary progressive MS without superimposed relapses Relevant cardiac, hepatic and renal diseases as specified in the protocol Pretreatment with immunosuppressants and immunomodulating drugs as specified in the protocol Clinical significant abnormalities in blood cell counts and immunoglobulin levels as specified in the protocol Clinical significant acute or chronic infections as specified in the protocol Other protocoldefined exclusion criteria could apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>Atacicept</keyword>
</DOC>